FDA’s Psychedelic Push: Corporate Capture of Mental Health Solutions Amidst Crisis of Care
Original framing: “FDA's Makary on Trump EO to Ease Access to Psychedelics” — Bloomberg
The original framing omits the colonial history of psychedelic prohibition and its disproportionate impact on Indigenous and Black communities, as well as the erasure of traditional use by Indigenous healers like the Mazatec of Oaxaca or the Shipibo-Conibo of the Amazon. It also ignores the lack of diversity in clinical trials, the racial biases in mental health diagnosis, and the structural violence of a healthcare system that prioritizes profit over prevention. Additionally, it fails to contextualize this trend within the broader crisis of care under neoliberalism, where mental health is commodified rather than treated as a public good.
Medium structural omission detected in mainstream coverage.
The narrative is produced by Bloomberg, a platform aligned with financial elites and corporate interests, amplifying FDA Commissioner Makary—a figure embedded in neoliberal health policy circles. The framing serves pharmaceutical companies, venture capitalists, and tech billionaires seeking to monetize psychedelic therapies, while obscuring the role of systemic underfunding in public mental health infrastructure. The discourse excludes critiques from grassroots organizers and Indigenous practitioners who have long warned against the co-optation of sacred medicines.
The criminalization of psychedelics in the 1960s was not merely a public health decision but a tool of political repression, targeting Black and Indigenous activists, anti-war movements, and countercultural figures. The current 'psychedelic renaissance' mirrors earlier cycles of medicalization and commodification, such as the 19th-century patent medicine industry or the 20th-century rise of Big Pharma. The FDA’s involvement today echoes its historical role in gatekeeping drugs for profit, as seen with the opioid crisis, where regulatory capture led to mass addiction and death.
The FDA’s push to fast-track psychedelics under Trump’s executive order is not a neutral public health intervention but a symptom of neoliberalism’s latest frontier: the financialization of consciousness.